Tirzepatide vs Semaglutide: Which Weight Loss Medication Works Better?

## Tirzepatide vs Semaglutide: Mechanism, Efficacy, and Clinical Evidence Tirzepatide and semaglutide represent two distinct approaches to GLP-1-based weight management. Both target the GLP-1 receptor, but tirzepatide additionally activates GIP receptors — a dual mechanism that clinical trials suggest may produce greater average weight reduction.

Parameter	Semaglutide	Tirzepatide
Mechanism	GLP-1 agonist	Dual GIP/GLP-1 agonist
Avg Weight Loss	14.9% (68 wks)	20.9% (72 wks)
Key Trial	STEP-1 (NEJM 2021)	SURMOUNT-1 (NEJM 2022)
Dose Range	0.25-2.4mg weekly	2.5-15mg weekly
HbA1c Reduction	~1.5%	~2.1%
Nausea Rate	~44%	~29%
FDA Approved	Yes (Wegovy 2021)	Yes (Zepbound 2023)

## How They Work: One Receptor vs. Two **Semaglutide (Ozempic/Wegovy)** activates a single target -- the GLP-1 receptor. This slows gastric emptying, reduces appetite, and improves insulin signaling. The STEP 1 trial demonstrated a mean weight loss of 14.9% of body weight over 68 weeks at the 2.4mg dose (Wilding et al., NEJM 2021). **Tirzepatide (Mounjaro/Zepbound)** hits two targets -- both the GLP-1 and GIP receptors. GIP receptor activation appears to amplify insulin sensitivity and fat metabolism beyond what GLP-1 alone achieves. In the SURMOUNT-1 trial, the 15mg dose produced a mean 20.9% body weight reduction over 72 weeks (Jastreboff et al., NEJM 2022). Worth noting: we have seen patients respond dramatically to one medication and modestly to the other. Receptor sensitivity varies person to person. For patients exploring even more advanced options, [retatrutide adds a third receptor target](/guides/retatrutide-weight-loss-triple-agonist-guide-2026) -- glucagon -- to the mix. ## Weight Loss: What the Trials Actually Found The SURPASS-2 trial (Frias et al., NEJM 2021) is the closest thing we have to a head-to-head comparison -- it tested tirzepatide against semaglutide 1mg in patients with type 2 diabetes. Tirzepatide won across the board for both A1C reduction and weight loss. However, semaglutide was dosed at 1mg (not the weight-loss dose of 2.4mg), so the comparison has limitations. | Metric | Semaglutide 2.4mg | Tirzepatide 15mg | |--------|-------------------|------------------| | Mean Body Weight Loss | 15-17% | 20.9% | | Patients Losing 20%+ | ~35% | ~57% | | A1C Reduction | 1.5-2.0% | 2.0-2.5% | | Trial Duration | 68 weeks | 72 weeks | For a 220-pound patient, that translates to roughly 33-37 lbs on semaglutide versus 46 lbs on tirzepatide. Significant -- but individual results swing widely around these averages. ## Dosing: Different Scales, Same Weekly Schedule Both medications are injected once per week. The titration paths look different: **Semaglutide:** 0.25mg > 0.5mg > 1mg > 1.7mg > 2.4mg (maximum) **Tirzepatide:** 2.5mg > 5mg > 7.5mg > 10mg > 12.5mg > 15mg (maximum FDA-approved) Tirzepatide has more dose steps, which clinicians find helpful. A patient who plateaus at 10mg can try 12.5mg before jumping to 15mg. In our experience, many patients find their sweet spot between 7.5mg and 10mg of tirzepatide. For a detailed walkthrough of each dose level, see our [complete tirzepatide dosing schedule guide](/guides/tirzepatide-dosing-schedule-complete-guide). ## Side Effects: Similar, but Not Identical Both medications cause GI side effects during dose escalation -- nausea, diarrhea, constipation, and reduced appetite. These are class effects tied to GLP-1 receptor activation. A few distinctions worth knowing: - **Sulfur burps** are more frequently reported with tirzepatide. Limiting carbonated drinks and high-fat meals helps. - **Injection site reactions** occur at similar rates for both. - **Severe GI events** (pancreatitis, gallbladder issues) are rare with either drug. One clinical pearl: patients who could not tolerate semaglutide sometimes do fine on tirzepatide, and vice versa. Our [semaglutide side effects management guide](/guides/semaglutide-side-effects-how-to-manage) covers strategies that apply to both medications. ## Cost Reality Check | Option | Monthly Cost | |--------|-------------| | Wegovy (brand semaglutide) | $1,300-1,500 | | Zepbound (brand tirzepatide) | $1,000-1,200 | | Compounded semaglutide | $200-400 | | Compounded tirzepatide | $250-450 | Insurance coverage is unpredictable. Mounjaro often gets covered under diabetes diagnoses. Zepbound coverage for obesity is expanding but still inconsistent. Both manufacturers offer savings programs. When we run cost-per-percentage-of-weight-lost, tirzepatide often comes out ahead despite higher absolute cost. For a full breakdown, check our [tirzepatide cost and pricing guide](/guides/tirzepatide-cost-price-guide-2026). ## Who Should Consider Which? **Semaglutide may be the better starting point if** you have existing insurance coverage for Wegovy/Ozempic, you are primarily managing type 2 diabetes, or you prefer a medication with a longer real-world track record. **Tirzepatide may be the better fit if** maximizing weight loss is your primary goal, you have stalled on semaglutide, you have significant insulin resistance, or you are starting GLP-1 therapy for the first time. ## Switching Between Them Moving from semaglutide to tirzepatide is common and straightforward. Take your last semaglutide dose, wait one week, and begin tirzepatide at 2.5mg. Do not try to match doses -- always start at the bottom of the titration schedule. We cover this process in depth in our [switching from semaglutide to tirzepatide guide](/guides/switching-from-semaglutide-to-tirzepatide-complete-guide). Switching from tirzepatide to semaglutide is less common but sometimes happens due to cost or insurance changes. Same principle: stop one, wait a week, start the other low. ## The Bottom Line Both medications are genuine breakthroughs. Tirzepatide produces about 25-35% more weight loss on average, but semaglutide has a longer track record and broader insurance coverage. The "best" medication is the one your body responds to, that you can afford, and that your provider can monitor effectively. *Medical disclaimer: This comparison is for educational purposes. Medication selection should be made with a healthcare provider — [find a clinic near you](/for-clinics) who knows your medical history.* --- ## References - [SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). *New England Journal of Medicine*, 2022. - [SURPASS-2: Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519). *New England Journal of Medicine*, 2021. - [STEP 1: Semaglutide 2.4 mg for Weight Management](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). *New England Journal of Medicine*, 2021. - [Mounjaro (tirzepatide) Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf). *Eli Lilly and Company*, 2024.